Crohn’s Disease (Regional Enteritis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Crohn’s Disease (Regional Enteritis) pipeline market research report provides comprehensive information on the therapeutics under development for Crohn’s Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn’s Disease (Regional Enteritis) and features dormant and discontinued projects.
Key Targets in the Regional Enteritis Pipeline Market
The key targets in the regional enteritis pipeline market are Interleukin 23 Subunit Alpha, Tumor Necrosis Factor, Interleukin 12 Subunit Beta, Integrin Alpha 4, Tyrosine Protein Kinase JAK1, Cannabinoid Receptor 1, and Cannabinoid Receptor 2. Interleukin 23 Subunit Alpha has the highest number of pipeline products.
Regional Enteritis Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Regional Enteritis Pipeline Market
The key MoA in the regional enteritis pipeline market are Interleukin 23 Subunit Alpha Inhibitor, Tumor Necrosis Factor Inhibitor, Interleukin 12 Subunit Beta Inhibitor, Integrin Alpha 4 Antagonist, Tyrosine Protein Kinase JAK1 Inhibitor, and Cannabinoid Receptor 1 Agonist. Interleukin 23 Subunit Alpha Inhibitor has the highest number of pipeline products.
Regional Enteritis Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Regional Enteritis Pipeline Market
The key RoA in the regional enteritis pipeline market are oral, subcutaneous, intravenous, topical, rectal, nasal, and parenteral. Oral has the highest number of pipeline products.
Regional Enteritis Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Regional Enteritis Pipeline Market
The key molecule types in the regional enteritis pipeline market are small molecule, monoclonal antibody, biologic, cell therapy, recombinant protein, polysaccharide, and gene-modified cell therapy. Small molecule has the highest number of pipeline products.
Regional Enteritis Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Regional Enteritis Pipeline Market
The key companies in the regional enteritis pipeline market are AbbVie Inc, Johnson & Johnson, Dadang & BIO Co Ltd, Boehringer Ingelheim International GmbH, Landos Biopharma Inc, Takeda Pharmaceutical Co Ltd, and Bristol-Myers Squibb Co. AbbVie Inc has the highest number of pipeline products.
Regional Enteritis Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
| Key targets | Interleukin 23 Subunit Alpha, Tumor Necrosis Factor, Interleukin 12 Subunit Beta, Integrin Alpha 4, Tyrosine Protein Kinase JAK1, Cannabinoid Receptor 1, and Cannabinoid Receptor 2 |
| Key MoA | Interleukin 23 Subunit Alpha Inhibitor, Tumor Necrosis Factor Inhibitor, Interleukin 12 Subunit Beta Inhibitor, Integrin Alpha 4 Antagonist, Tyrosine Protein Kinase JAK1 Inhibitor, and Cannabinoid Receptor 1 Agonist |
| Key RoA | Oral, Subcutaneous, Intravenous, Topical, Rectal, Nasal, and Parenteral |
| Key molecule types | Small Molecule, Monoclonal Antibody, Biologic, Cell Therapy, Recombinant Protein, Polysaccharide, and Gene-Modified Cell Therapy |
| Key companies | AbbVie Inc, Johnson & Johnson, Dadang & BIO Co Ltd, Boehringer Ingelheim International GmbH, Landos Biopharma Inc, Takeda Pharmaceutical Co Ltd, and Bristol-Myers Squibb Co |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn’s Disease (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Crohn’s Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Crohn’s Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Crohn’s Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Crohn’s Disease (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crohn’s Disease (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crohn’s Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key targets in the regional enteritis pipeline market are Interleukin 23 Subunit Alpha, Tumor Necrosis Factor, Interleukin 12 Subunit Beta, Integrin Alpha 4, Tyrosine Protein Kinase JAK1, Cannabinoid Receptor 1, and Cannabinoid Receptor 2.
The key MoA in the regional enteritis pipeline market are Interleukin 23 Subunit Alpha Inhibitor, Tumor Necrosis Factor Inhibitor, Interleukin 12 Subunit Beta Inhibitor, Integrin Alpha 4 Antagonist, Tyrosine Protein Kinase JAK1 Inhibitor, and Cannabinoid Receptor 1 Agonist.
The key RoA in the regional enteritis pipeline market are oral, subcutaneous, intravenous, topical, rectal, nasal, and parenteral.
The key molecule types in the regional enteritis pipeline market are small molecule, monoclonal antibody, biologic, cell therapy, recombinant protein, polysaccharide, and gene-modified cell therapy.
The key companies in the regional enteritis pipeline market are AbbVie Inc, Johnson & Johnson, Dadang & BIO Co Ltd, Boehringer Ingelheim International GmbH, Landos Biopharma Inc, Takeda Pharmaceutical Co Ltd, and Bristol-Myers Squibb Co.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Gastrointestinal reports